×

Distinguishing PCA3 messenger RNA species in benign and malignant prostate tissues

  • US 8,618,276 B2
  • Filed: 08/02/2012
  • Issued: 12/31/2013
  • Est. Priority Date: 09/29/1999
  • Status: Expired due to Fees
First Claim
Patent Images

1. A prostate cancer-classifying composition comprising:

  • (a) a PCA3 nucleic acid molecule comprising an additional sequence between PCA3 exon 3 and PCA3 exon 4a, said additional sequence corresponding essentially to nucleotides 27 to 254 of SEQ ID NO;

    1, wherein said PCA3 nucleic acid molecule is from a prostate cell of a human subject having or suspected of having prostate cancer; and

    (b) at least one oligonucleotide enabling the determination of whether said PCA3 nucleic acid molecule RNA comprises or lacks said additional sequence between PCA3 exon 3 and PCA3 exon 4a,wherein the presence or level of a PCA3 nucleic acid molecule lacking said additional sequence indicates that said prostate cells comprise prostate cancer cells.

View all claims
  • 4 Assignments
Timeline View
Assignment View
    ×
    ×